Novartis announced Friday that it had received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis® (ranibizumab) to treat patients in the European Union with visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
Lucentis was shown to improve vision and vision related quality of life for patients with visual impairment due to macular edema secondary to both branch-RVO (BRVO) a (Read more...)